Financial Toxicity Rife Among Patients With Multiple Myeloma

This article originally appeared here.
Share this content:
Financial Toxicity Rife Among Patients With Multiple Myeloma
Financial Toxicity Rife Among Patients With Multiple Myeloma

FRIDAY, Sept. 18, 2015 (HealthDay News) -- Insured patients with multiple myeloma frequently report financial toxicity and use of coping mechanisms, according to a study published online Sept. 16 in The Lancet Haematology.

Scott F. Huntington, M.D., from the University of Pennsylvania in Philadelphia, and colleagues conducted a cross-sectional survey of 100 individuals receiving at least three months of treatment for multiple myeloma. The survey included the 11-item COST measure, which gives a financial toxicity score ranging from 0 to 44.

The researchers found that 59 percent of patients reported that treatment costs were higher than expected, while 71 and 36 percent, respectively, reported having at least minor financial burden and applying for financial assistance. Patients often used savings to pay for myeloma treatment (46 percent), and 21 percent reported borrowing money to pay for medications. There was a strong correlation for COST scores with patient-reported use of strategies to cope with myeloma treatment expenses. Younger age, nonmarried status, longer duration since diagnosis, and lower household income correlated with higher financial burden, as measured by the COST score, in multivariable analysis.

"Additional attention to rising treatment costs and cost sharing is needed to address the increasing evidence of financial toxicity affecting patients with cancer," the authors write.

Several authors disclosed financial ties to the biopharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »